


Please type a plus (+) inside this box → 

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
(If the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.)

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	8661-010-999	Total Pages	35
First Named Inventor or Application Identifier			
Richard Allen et al.			
Express Mail Label No.	EM38514341US		

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing)

2. ☒ Specification [Total Pages 33]
(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings *(if filed)*
- Claim(s)
- Abstract of the Disclosure

3. ☒ Drawing(s) *(35 USC 113)* [Total Sheets 2]

4. ☒ Oath or Declaration [Total Sheets 2]

- a. ☒ Unexecuted (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

i. ☐ **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).

5. ☐ Incorporation By Reference *(useable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

- 6. ☐ Microfiche Computer Program *(Appendix)*
- 7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8. ☐ Assignment Papers (cover sheet & document(s))
- 9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
- 10. ☐ English Translation Document *(if applicable)*
- 11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
- 12. ☐ Preliminary Amendment
- 13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 14. ☐ Small Entity ☐ Statement filed in prior application, Statement(s) Status still proper and desired
- 15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- 16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: filed .

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

20583
(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

ADDRESS

CITY

STATE

ZIP CODE

COUNTRY

TELEPHONE

FAX

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PENNIE & EDMONDS LLP

COUNSELLORS AT LAW
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

01/02/98
JCS60 U.S. PAT.

ATTORNEY DOCKET NO. 8661-010

Date January 2, 1998

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Richard Allen et al.

Executed on:

Title of Invention: USE OF PIGMENTED RETINAL EPITHELIAL CELLS FOR CREATION OF AN IMMUNE
PRIVILEGE SITE

Pages of Specification 32 + Abstract

Sheets of Drawings 2

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	35	-20	15	\$22.00 each	330.00
Independent	11	-3	8	\$82.00 each	656.00
Minimum Fee					790.00
Multiple Dependency Fee If Applicable (\$270.00)					270.00
Total					2,046.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					-
Total Filing Fee					\$ 2,046.00

Priority of application no. filed on in is claimed under 35 U.S.C. § 119.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this
sheet is enclosed.

Respectfully submitted,

Samuel B. Abrams
PENNIE & EDMONDS LLP

30605
(Reg. No.)

Enclosure

This form is not for use with re-issue, design or plant patent applications.

USE OF PIGMENTED RETINAL EPITHELIAL CELLS
FOR CREATION OF AN IMMUNE PRIVILEGE SITE

1. INTRODUCTION

5 The present invention relates to a novel *in vivo* method
for creation of a localized immunosuppressive environment in
tissue. The method involves the transplanting of pigmented
retinal epithelial cells into a mammal thereby producing a
localized immunosuppressive environment. The transplanted
10 pigmented retinal epithelial cells may also be used to
produce therapeutic proteins or other biologically active
molecules that may be useful in treatment of diseases.

2. BACKGROUND OF THE INVENTION

15 Certain chronic diseases result in the destruction of
functional cells in affected organs. Mammals with such
diseases are frequently unable to produce proteins or
hormones necessary to maintain normal physiological function.
In such instances, transplantation of healthy organs or cells
20 into the affected mammal may alleviate the symptoms of the
disease. The transplantation of cells and tissues is being
utilized therapeutically in a wide range of disorders
including but not limited to cystic fibrosis (lungs), kidney
failure, degenerative heart diseases, diabetes,
25 neurodegenerative disorders, liver failure and pancreatic
failure.

 Unfortunately, such transplants are often rejected by
the body due to an immune response initiated in response to
the foreign tissue or cells. Presently, the only recourse to
prevent the rejection of the transplanted tissue is to
30 administer immunosuppressive agents, but the individual is
placed at medical risk making the immunosuppressant therapy
itself more of a liability than a benefit in some cases.
Therefore, the benefits of transplantation have been limited
by the serious side effects of systemic immunosuppression,
35 which is necessary if successful transplantation is to be
achieved in humans.

It has recently been discovered that immune-privileged sites exist in the body where grafted tissue can survive for prolonged periods of time (Streiland, J.W., 1995, Science 270:1158-1159). Such sites include, for example, the eye, testes, and brain. The features of the privileged sites include intratissue structural barriers such as the presence of a blood-tissue barrier, absence of efferent lymphatics and direct drainage of tissue fluid into the blood. Additional features of immune privileged sites include the establishment of an immunosuppressive environment through secretion of immunosuppressive cytokines such as TGF β or Fas L. The Fas L protein is believed to be particularly important for the prolonged survival of grafted tissue and is believed to act through activation of apoptosis in Fas+, antigen activated T cells of the recipient (Griffith, T.S. et al., 1995, Science 270:1189-1192).

The eye, an organ segregated into two anatomically distinct regions, is a particularly interesting example of an immune privileged site. The immune privilege in the anterior chamber is believed due to Fas L, while that in the posterior chamber is believed due to the physical barrier created by the RPE cells of the retina, segregating the posterior chamber from the immune cells of the blood. Based on this, it would be surprising indeed if isolated RPE cells, no longer in a tight confluent layer, could produce an immune privileged site.

The present invention is based on the discovery that retinal pigmented epithelial cells secrete Fas L and are capable of functioning outside of the structural confines of the retina to produce an immune privileged site. The expression of Fas L protein by retinal pigmented epithelial cells is surprising given the fact that they also express the receptor for Fas L (Esser, et al., 1995, Bioch. Biophys. Res. Com. 213:1206-1034). Nevertheless, the cells seem resistant to the signals for apoptosis.

The present invention is based on discovery that human retinal epithelial cells secrete the Fas L protein.

Expression of Fas L in the immune-privileged site of the eye, is believed to directly kill activated lymphocytes that might invade the eye in response to inflammation and thereby destroy vision by reacting with important structures such as the retina. The expression of the Fas L protein by retinal epithelial cells is surprising given the fact that the human retinal epithelial cells also express the receptor for Fas L (Esser et al., 1995, Bioch. Biophys. Res. Com. 213:1026-1034). Nevertheless, the cells seem resistant to the signals for apoptosis.

Recently, studies have suggested that Sertoli cells, when simultaneously transplanted with pancreatic islet cell into the diabetic rat, act as an effective local immunosuppressant on the host tissue (Selawry and Cameron, 1993, Cell Transplantation 2:123-129). This cell transplantation protocol is accomplished without prolonged systemic immunosuppression, otherwise necessary when islets are transplanted without Sertoli cells. As a result, the graft is not rejected and the islets remain viable allowing the transplanted pancreatic islet cells to function normally and produce insulin for an indefinite period of time. Survival of the graft seems to correlate with constitutive expression of Fas L by the Sertoli cells.

The development of methods designed to enhance productive cell transplantation techniques would be useful for the treatment of diseases, such as Parkinson's disease, and diabetes. Likewise, it is desirable to avoid systemic immunosuppression with the ability to locally immunosuppress (*i.e.*, at the graft site) by administration of an immunosuppressant that is biologically tolerated by the host. Therefore, the identification of cells capable of delivering local immunosuppression and promoting efficient graft acceptance and functional restoration of the tissue-related dysfunction is desirable.

35

3. SUMMARY OF THE INVENTION

The present invention relates to a novel method for creation of an immunologically privileged site in a mammal. The method of the invention comprises the transplantation of
5 retinal pigment epithelial (RPE) cells, thereby producing a localized immunosuppressive environment at the site of transplantation. The present invention relates to the discovery that RPE cells secrete large quantities of the immunosuppressive cytokine referred to as Fas-Ligand (Fas L).
10 The Fas L protein is believed to exert its immune suppressive effect by stimulating apoptosis in Fas+ antigen activated T cells of the recipient. In addition to immunosuppressive cytokines, the RPE cells produce additional biological factors such as growth factors, cytokines, and hormones that
15 may be useful in treating a wide range of different diseases.

The invention further relates to the co-administering of RPE cells together with cells that supply a functionally active therapeutic molecule as a method of treating diseases resulting from a deficiency of a biological factor in a
20 mammal. In instances where the RPE cells are co-administered with cells and/or matrices supplying therapeutic molecules, the RPE cells may be co-administered either as a single composition, or alternatively, as separate compositions. When the RPE cells are administered as a separate
25 composition, the RPE cells may be administered prior to co-administration of cells that supply a therapeutic, protein or biologically active molecule, in a sufficient amount for creation of an immune privilege site. The co-administering of RPE cells has the advantage in that the RPE cells create
30 an immunologically privileged site thereby increasing the survival time of the co-administered cells. Co-administered cells producing functionally active proteins or biologically active molecules, include but are not limited to, insulin producing β -cells, dopamine producing neural or non-neural
35 cells or hormone producing endocrine cells.

In yet another embodiment of the invention, RPE cells may be genetically engineered to produce a therapeutic

protein or biologically active molecule that may be useful in treating disease. For example, the RPE cells may be genetically engineered to produce a wide range of proteins including but not limited to, growth factors, cytokines, or

5 biologically active molecules such as hormones. The ability of RPE cells to suppress the normal graft rejection response ordinarily stimulated in the recipient host increases the growth and viability of the transplanted RPE cells. The invention further relates to the *in vitro* attachment of RPE

10 cells to the same or different matrix for the purpose of increasing the long term viability of the transplanted cells. In addition, co-administered cells producing therapeutic proteins or biologically active molecules, may be attached to the same or different matrix prior to transplantation.

15 Materials of which the support matrix can be composed include those material to which cells adhere following *in vitro* incubation, on which cells can grow, and which can be implanted into the mammalian body without producing a toxic reaction, or an inflammatory reaction which would destroy the

20 implanted cells.

The invention provides for pharmaceutical compositions comprising RPE cells and a pharmaceutically acceptable carrier. The invention further encompasses pharmaceutical compositions comprising RPE cells and cells producing a

25 functionally active therapeutic protein, or biologically active molecule, contained in a pharmaceutically acceptable carrier. The compositions of the invention may be utilized for treatment of diseases where the creation of an immunologically privileged site and the administration of a

30 functionally active therapeutic protein, or other biologically active molecule, is desired. Such diseases include neurological, cardiac, endocrine, hepatic, pulmonary, metabolic or immunological related diseases. For example, neurological disorders such as Parkinson's disease,

35 Huntington's disease, Alzheimer's disease, ALS, stroke and traumatic head and spinal injury may be treated. Non-

neurological diseases include, but are not limited to, diabetes, blood clotting disorders, and cystic fibrosis.

5

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. FACS analysis of Fas L induced apoptosis. The presence of apoptotic cells is demonstrated by increased fluorescence intensity. The percent of apoptotic cells
10 increases in proportion to the level of Fas L present in the media.

FIG. 2. FACS analysis of Fas L induced apoptosis. Increased apoptosis in the presence of Fas L is indicated in
15 the accompanying table inserts presented below each FACS analysis.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method of producing a
20 sustained localized immunosuppressive effect in tissue. This is achieved by the general step of transplanting RPE cells into host recipient tissue. By sustained localized immunosuppressive effect, it is meant that the transplanted RPE cells will suppress the immunological response ordinarily
25 mounted by the host tissue to foreign entities such as transplanted cells and that the immunosuppression will occur at the graft site (local) rather than by generalized immunosuppression of the entire body (systemic) which occurs with the ordinary methods of immunosuppression by agents such
30 as cyclosporine.

In a preferred embodiment, the transplanted RPE cells (which are intended to replace dysfunctional cells or in some way alleviate tissue dysfunction) can avoid being rejected and thereby survive and functionally integrate into the host
35 tissue. Furthermore, the method of the present invention can also be utilized wherein RPE cells are co-administered with additional cells or tissues, such as neural cells, endocrine

cells, muscle cells, and other cells that produce a functionally active therapeutic molecules. In addition, the RPE cells may be attached *in vitro* prior to transplantation to a natural or synthetic matrix that increases the long term viability of the transplanted cells. The method of the present invention may be used for enhancing the outcome of tissue transplants, by providing localized immunosuppression. That is, RPE cells may be used to facilitate transplant survival and graft function of the cells being transplanted.

10 The present invention is based on the discovery that RPE cells secrete the immunosuppressive cytokine Fas L. The Fas L protein has been shown to prolong the viability of grafted tissue through activation of apoptosis in Fas+ antigen activated lymphocytes of the recipient.

15 With local immunosuppression by a RPE cell-derived immunosuppressant agent, such as Fas L, there would be no cellular immunological attack waged against the transplanted cells, including the RPE cells themselves. Additionally, since the immunosuppression is local and by a biologically tolerable agent, the side effects associated with both systemic immunosuppression and cytotoxicity of agents such as cyclosporine would be avoided. Hence, the method of RPE cell transplantation provides a significant improvement over the use of systemic immunosuppression with cyclosporine as the necessary adjunctive therapy to transplantation.

25 The localized immunosuppression by a RPE cell-derived immunosuppressant agent, such as Fas L, can facilitate the survival of both xenografts and allografts. With allografts, co-transplantation with RPE cells should provide localized immunosuppression as to eliminate the need for systemic immunosuppression. With xenografts, co-transplantation with RPE cells may provide sufficient local immunosuppression so as to eliminate the need for systemic immunosuppression or the RPE cells may be used in combination with a systemic immunosuppressant to prevent rejection thereby reducing the dosage of systemic immunosuppressant required. When co-transplanted, the RPE cells may not only provide

immunosuppression, but may provide regulatory, nutritional, and other factors which support the survival and/or growth of co-transplanted tissue. Therefore, the RPE cells will not only provide inhibition of the immune response, but will
5 allow enhanced growth and viability of allografts and xenografts by concomitant trophic support.

5.1. SOURCES OF RPE CELLS

The source of RPE cells is by primary cell isolation
10 from the mammalian retina. Protocols for harvesting RPE cells is well-defined (Liu and Turner, 1988, Exp. Eye Res 47:911-917; Lopez et al., 1989, Invest Ophthalmol Vis Sci. 30:586-588) and considered a routine methodology (see below, Section 6.6.1.). In most of the published reports of RPE
15 cell co-transplantation, cells are derived from the rat (Liu and Turner, 1988, Exp. Eye Res 47:911-917; Lopez et al., 1989, Invest Ophthalmol Vis Sci. 30:586-588), although, it is contemplated that the method of the present invention can be used with RPE cells from any suitable mammalian source. A
20 preferred source of RPE cells for use with mammals, such as humans, are human RPE cells. However, if available and suitable, porcine RPE cells may be utilized. In addition, to isolated primary RPE cells, cultured human and animal RPE cell lines may be used in the practice of the invention.
25 The methods of the invention further encompass the transplantation of RPE cells genetically engineered to express functionally active therapeutic proteins, enzymes that produce biologically active factors or biologically active molecules.
30 The present methods and compositions may employ RPE cells genetically engineered to produce a wide range of functionally active therapeutic proteins, enzymes that produce biologically active factors or biologically active molecules including growth factors, cytokines, hormones and
35 peptide fragments of hormones, inhibitors of cytokines, peptide growth and differentiation factors, interleukins, chemokines, interferons, colony stimulating factors and

angiogenic factors. Examples of such proteins include, but are not limited to, the superfamily of TGF- β molecules, including the five TGF- β isoforms and bone morphogenetic proteins (BMP), latent TGF- β binding proteins, LTBP;

- 5 keratinocyte growth factor (KGF); hepatocyte growth factor (HGF); platelet derived growth factor (PDGF); insulin-like growth factor (IGF); the basic fibroblast growth factors (FGF-1, FGF-2 etc.), vascular endothelial growth factor (VEGF); Factor VIII and Factor IX; erythropoietin (EPO);
10 tissue plasminogen activator (TPA); activins and inhibins. Hormones which may be used in the practice of the invention include growth hormone (GH) and parathyroid hormone (PTH).

- One may obtain the DNA segment encoding the protein of interest using a variety of molecular biological techniques,
15 generally known to those skilled in the art. For example, cDNA or genomic libraries may be screened using primers or probes with sequences based on the known nucleotide sequences. Polymerase chain reaction (PCR) may also be used to generate the DNA fragment encoding the protein of
20 interest. Alternatively, the DNA fragment may be obtained from a commercial source.

- The DNA encoding the translational or transcriptional products of interest may be recombinantly engineered into variety of vector systems that provide for replication of the
25 DNA in large scale for the preparation of genetically engineered RPE cells. These vectors can be designed to contain the necessary elements for directing the transcription and/or translation of the DNA sequence in RPE cells.

- 30 Vectors that may be used include, but are not limited to those derived from recombinant bacteriophage DNA, plasmid DNA or cosmid DNA. For example, plasmid vectors such as pBR322, pUC 19/18, pUC 118, 119 and the M13 mp series of vectors may be used. Bacteriophage vectors may include λ gt10, λ gt11,
35 λ gt18-23, λ ZAP/R and the EMBL series of bacteriophage vectors. Cosmid vectors that may be utilized include, but are not limited to, pJB8, pCV 103, pCV 107, pCV 108, pTM,

pMCS, pNNL, pHSG274, COS202, COS203, pWE15, pWE16 and the charomid 9 series of vectors. Alternatively, recombinant virus vectors including, but not limited to those derived from viruses such as herpes virus, retroviruses, vaccinia
5 viruses, adenoviruses, adeno-associated viruses or bovine papilloma virus may be engineered.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing the protein coding sequence operatively associated with
10 appropriate transcriptional/translational control signals. These methods include *in vitro* recombinant DNA techniques, and synthetic techniques. See, for example, the techniques described in Sambrook, et al., 1992, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. and
15 Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates & Wiley Interscience, N.Y.

The genes encoding the proteins of interest may be operatively associated with a variety of different promoter/enhancer elements. The expression elements of these
20 vectors may vary in their strength and specificities. Depending on the host/vector system utilized, any one of a number of suitable transcription and translation elements may be used. The promoter may be in the form of the promoter which is naturally associated with the gene of interest.
25 Alternatively, the DNA may be positioned under the control of a recombinant or heterologous promoter, i.e., a promoter that is not normally associated with that gene. For example, RPE specific promoter/enhancer elements may be used to regulate the expression of the transferred DNA in RPE cells.

30 In some instances, the promoter elements may be constitutive or inducible promoters and can be used under the appropriate conditions to direct high level or regulated expression of the gene of interest. Expression of genes under the control of constitutive promoters does not require
35 the presence of a specific substrate to induce gene expression and will occur under all conditions of cell growth. In contrast, expression of genes controlled by

inducible promoters is responsive to the presence or absence of an inducing agent.

Specific initiation signals are also required for sufficient translation of inserted protein coding sequences.

- 5 These signals include the ATG initiation codon and adjacent sequences. In cases where the entire coding sequence, including the initiation codon and adjacent sequences are inserted into the appropriate expression vectors, no additional translational control signals may be needed.
- 10 However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the protein coding sequences to ensure
- 15 translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency and control of expression may be enhanced by the inclusion of transcription attenuation sequences, enhancer
- 20 elements, etc.

- It is also within the scope of the invention that multiple genes, combined on a single genetic construct under control of one or more promoters, or prepared as separate constructs of the same or different types may be used. Thus,
- 25 an almost endless combination of different genes and genetic constructs may be employed. Certain gene combinations may be designed to, or their use may otherwise result in, achieving synergistic effects on cell stimulation any and all such combinations are intended to fall within the scope of the
- 30 present invention. Indeed, many synergistic effects have been described in the scientific literature, so that one of ordinary skill in the art would readily be able to identify likely synergistic gene combinations, or even gene-protein combinations.

- 35 For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of

replication, host RPE cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker.

- 5 Following the introduction of the foreign DNA, engineered RPE cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably
- 10 integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express a therapeutic gene product of interest.
- 15 To increase the long term viability of the transplanted cells, i.e., transplanted RPE cells or co-administered cells, the cells to be transplanted can be attached *in vitro* to a support matrix prior to transplantation. Materials of which the support matrix can be comprised include those materials
- 20 to which cells adhere following *in vitro* incubation, and on which cells can grow, and which can be implanted into the mammalian body without producing a toxic reaction, or an inflammatory reaction which would destroy the implanted cells or otherwise interfere with their biological or therapeutic
- 25 activity. Such materials may be synthetic or natural chemical substances or substances having a biological origin. The matrix materials include, but are not limited to, glass and other silicon oxides, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane,
- 30 polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentent, nylon, amylases, natural and modified gelatin and natural and modified collagen, natural and modified polysaccharides, including dextrans and celluloses (e.g. nitrocellulose),
- 35 agar, and magnetite. Either resorbable or non-resorbable materials may be used. Also intended are extracellular matrix materials, which are well-known in the art.

Extracellular matrix materials may be obtained commercially or prepared by growing cells which secrete such a matrix, removing the secreting cells, and allowing the cells which are to be transplanted to interact with and adhere to the
5 matrix. The matrix material on which the cells to be implanted grow, or with which the cells are mixed, may be an indigenous product of the RPE cells themselves. Thus, for example, the matrix material may be extracellular matrix or basement membrane material which is produced and secreted by
10 the RPE cells to be implanted.

To improve cell adhesion, survival and function, the solid matrix may optionally be coated on its external surface with factors known in the art to promote cell adhesion, growth or survival. Such factors include cell adhesion
15 molecules, extracellular matrix, such as, for example, fibronectin, laminin, collagen, elastin, glycosaminoglycans, or proteoglycans or growth factors, such as, for example, nerve growth factor (NGF). Alternatively, if the solid matrix to which the implanted cells are attached is
20 constructed of porous material, the growth- or survival-promoting factor or factors may be incorporated into the matrix material, from which they would be slowly released after implantation *in vivo*.

When attached to the support according to the present
25 invention, the cells used for transplantation are generally on the "outer surface" of the support. The support may be solid or porous. However, even in a porous support, the cells are in direct contact with the external milieu without an intervening membrane or other barrier. Thus, according to
30 the present invention, the cells are considered to be on the "outer surface" of the support even though the surface to which they adhere may be in the form of internal folds or convolutions of the porous support material which are not at the exterior of the particle or bead itself.

35 The configuration of the support is preferably spherical, as in a bead, but may be cylindrical, elliptical, a flat sheet or strip, a needle or pin shape, and the like.

A preferred form of support matrix is a glass bead. Another preferred bead is a polystyrene bead. Bead sizes may range from about 10 microns to 1 mm in diameter, preferably from about 90 to about 150 μm . For a description of various microcarrier beads, see, for example, Fisher Biotech Source 87-88, Fisher Scientific Co., 1987, pp. 72-75; Sigma Cell Culture Catalog, Sigma Chemical Co., St. Louis, 1991, pp. 162-163; Ventrex Product Catalog, Ventrex Laboratories, 1989; these references are hereby incorporated by reference. The upper limit of the bead's size may be dictated by the bead's stimulation of undesired host reactions, which may interfere with the function of the transplanted cells or cause damage to the surrounding tissue. The upper limit of the bead's size may also be dictated by the method of administration. Such limitations are readily determinable by one of skill in the art.

5.2. PHARMACEUTICAL FORMULATIONS AND METHODS OF CREATING AN IMMUNOLOGICALLY PRIVILEGED SITE

The present invention encompasses methods and compositions for creating a localized immunosuppressive environment. Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the RPE cells and any cells, tissue or matrices to be co-transplanted with the RPE cells, and physiologically acceptable salts and solvents may be formulated for administration by surgical transplantation or injection. As used herein, a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and the like. The use of such media and agents is well-known in the art.

The present invention also encompasses compartmentalized kits adapted to receive a container adapted to contain RPE cells and a second container adapted to contain cells that produce a therapeutic molecule. The invention also relates

to an article of manufacture comprising a packaging material and RPE cells contained within the packaging material.

The methods of the present invention, encompass the administration of RPE cells into a mammal so as to become
5 located in proximity to the selected tissue. For example, the location can be any site within the mammalian body such as endothelial tissue, muscle tissue, neural tissue and organs, etc. The proximity of the RPE cells to the tissue is determined by the specific tissue being transplanted and the
10 function sought to be restored in a given transplantation.

The administration of RPE cells is accomplished by conventional techniques. Preferred techniques for administration of RPE cells includes injection of RPE cells within the host or surgical transplantation of cells within
15 the host. Prior to transplantation, the recipient mammal may be anesthetized using local or general anesthesia according to conventional techniques.

The number of RPE cells needed to achieve the purposes of the present invention will vary depending on the specific
20 tissue being transplanted and the desired function of the RPE cells. For example, the RPE cells are administered in an amount effective to provide an immunologically privileged site. In general, such an effective amount is defined as that which prevents immune rejection of subsequently or
25 coadministered cells or tissue. The dose range of RPE cells to be used in the practice of the invention may vary between 10^3 - 10^9 cells, although the preferable dose of administered RPE cells will be between 10^5 - 10^7 cells. Immune rejection can be determined for example histologically, or by functional
30 assessment of the cotransplanted cells or tissue.

In an embodiment of the invention comprising the co-administration of cells producing a functionally active therapeutic protein or other biologically active molecule, together with RPE cells, the cells are administered in a
35 therapeutically affective amount. In such an embodiment of the invention, the RPE cells may be co-administered as a single composition, or alternatively, as two separate

compositions. Further, the RPE cells may be re-administered in an effective amount as necessary to sustain an immunologically privilege site. Alternatively, the co-administered cells that supply a therapeutic protein, or
5 other biologically active molecule, may be re-administered in an effective amount to sustain a therapeutic effect.

In yet another embodiment of the invention, the transplanted cells may be attached *in vitro* to a matrix prior to transplantation. The number of cells to be transplanted
10 can be determined by one of skill in the art by methods known in the art and will be dependent upon the amount of therapeutic protein or other biologically active molecule being produced by the cells and the known therapeutically effective amount of molecule necessary to treat the disease.

15

6. EXAMPLE: PRODUCTION OF IMMUNOLOGICALLY AND BIOLOGICALLY ACTIVE FAS L BY RPE CELLS

The section below describes experimental results demonstrating that retinal pigmented epithelial cells express
20 biologically active Fas L. Enzyme linked immunoassays with anti-Fas L antibody indicated that substantial amounts of Fas L was released into the culture media by the retinal pigmented epithelial cells. In addition, the secreted Fas L was biologically active in inducing apoptosis in human fetal
25 thymocytes.

6.1. MATERIALS AND METHODS

6.1.1. ISOLATION AND CULTURE OF RETINAL PIGMENTED EPITHELIAL CELLS

Primary isolates of RPE cells were made using human
30 fetal human eyes at 18-20 weeks of gestation. Fetal eyes are collected within 15 minutes of harvesting the conceptus and their external surface is briefly washed with cold, sterile saline solution to remove as much external contamination as possible. The eye tissue is transferred into a dissecting
35 dish containing solution A (RPMI 1640 culture media (Gibco, Cat. No. 22-400) to which a penicillin/streptomycin/fungizone

Stock Solution (Gibco, Cat. No. 15240-039) is added to give a final concentration of 2% vol./vol.

Using sterile forceps and scissors, excess fat tissue is trimmed from the eye tissue. Using a sterile, disposable scalpel, the eye tissue is sectioned just behind the iris and the frontal tissue discarded. The back 2/3 of eye tissue is sectioned from top to bottom with the scalpel and the inner faces of the two halves oriented face up. Each half is then affixed to the silicone layer in the bottom of the Dissecting Dish using 3-4 one inch, sterile, disposable 23 gauge needles (Baxter, Cat. No. 23G1). This exposes the pigmented retinal epithelial cell layers, which are gently teased away from the choroid membrane to which the RPE cell sheet is attached. Usually, two large sheets of RPE cells are recovered from each eye.

Once the RPE cell layer is detached, it is examined microscopically to determine if there is significant contamination with choroid membrane. The RPE cell layer is transferred from the dish into 10 ml of sterile Solution A. 20 Sterile filtered collagenase (Liberase™, Boehringer Mannheim) is added to a final concentration of 1 mg/ml. RPE tissue is transferred to a 37°C water bath and incubated for 15 minutes. The tube is then centrifuged at 100 x g for 5 min at room temperature in a Beckman bench top centrifuge 25 (Beckman, Model No. GPR). The tube is transferred back to the laminar flow hood and the aqueous phase gently aspirated. Ten ml of Culture Medium (RPMI 1640 containing 10% fetal calf serum, 2 mM glutamine, and acidic FGF, 10 ng/ml) is added and the RPE tissue in the pellet resuspended. A small aliquot of 30 the suspension is placed on a microscope slide and examined microscopically. The collagenase digestion step produces a limited fragmentation of the RPE cell sheath and removes the small residual choroid tissue and associated cell contaminants, but does not result in a dissociation of the 35 RPE cell layer into single cells.

RPE cells derived as described above were suspended in 10 ml of Culture Medium to which Stock Solution of

antibiotic/antimycotics added to a final concentration of 1%. All culture reagents (medium, serum, FGF, glutamine and the trypsin utilized for subculturing) have been qualified for GMP cell manufacturing by Washington Labs. These Qualified
5 reagents are supplied by Washington Labs for the initial phase of cell expansion of primary isolates of RPE tissue. The RPE cell suspension is transferred to 25 ml Falcon culture flasks that are coated with a recombinant attachment protein, Pronectin F (Protein Technologies, Cat. No. 5002-00,
10 Lot. No. R0117-c), to facilitate cell attachment.

Flasks are coated as follows: a 5 mg vial of sterile Pronectin F was dissolved in 5 ml of sterile diluent solution (lithium perchlorate in water) in a laminar flow hood. Aliquots are mixed with qualified Phosphate Buffered Saline
15 (PBS) (Gibco, Cat. No. 14287) to produce a Pronectin F concentration of 10 μ g/ml. Five ml of this solution is sterilely transferred into the Falcon culture flasks, which were allowed to stand in the laminar flow hood for two hours at room temperature. The solution is removed with a sterile
20 pipet and the flask rinsed twice with sterile Pronectin F-free PBS. The flasks were allowed to dry in the laminar flow hood after removal of the second rinse solution. The caps are tightened on the flasks and the flasks stored under refrigeration for up to 4 months for RPE cell culture.

25 The Pronectin-F coating facilitates cell division by a factor of 4-5 fold, compared to that seen with uncoated flasks. Results seen with Pronectin F are approximately equivalent to those seen with mouse laminin (Gibco, Cat. No. L2020) and human laminin (Sigma, placental derived, Cat.
30 No. L6274) coated culture flasks.

The initial culture of RPE cells is performed in Culture Medium to which Stock Solution antibiotic/antimycotic solution supplement is added to a final concentration of 1%. The cultures uniformly become contaminated by microbial
35 agents that are acquired by the tissue during transit through the birth canal, if the antibiotic/antimycotic solution supplement is added to a final concentration of 1%. The

cultures uniformly become contaminated by microbial agents that are acquired by the tissue during transit through the birth canal, if the antibiotic/antimycotic supplement is omitted from the Culture Medium. The antibiotic/antimycotic agents are maintained in the RPE cultures for approximately two weeks, with medium changes at least once weekly. Thereafter, the cultures are switched to antibiotic/antimycotic-free Culture Medium for an additional two weeks. Less than one culture in 10 presents evidence of contamination with bacteria, yeast or fungus after the shift to antibiotic/antimycotic-free medium, provided the antibiotic/antimycotic reagent is present from the time of tissue initiation.

The frequency of medium changes during the RPE cell culture is dictated by changes in glucose and lactate in the cultures. Following the initial plating of RPE cells, aliquots of medium are removed from the flasks once every two-three days and subjected to glucose and lactate analysis, using a YSI glucose-lactate analyzer (YSI, Model No. 2700). The analyzer is standardized at each assay using internal standards of glucose and lactate provided by YSI. If the analysis indicates that the cultures have consumed more than 1/2 to 2/3 of the glucose, the culture medium is changed. As a minimum, the culture medium is changed once weekly, to assure that effective concentrations of the antibiotic/antimycotic agents are maintained.

A comparison of glucose consumed to lactate produced is also determined. Uninfected culture medium exhibited a glucose:lactate ratio of 0.80:1 and greater in sparsely populated to near confluent cultures. Excessive lactate production by sparse cultures is viewed as an indication of contamination with bacteria and such cultures are discarded. Excessive consumption of glucose in the absence of approximately equivalent lactate accumulation is viewed as an indication of fungal or yeast contamination and such cultures are discarded.

Yields of RPE cells directly from a single eye range from approximately 250,000 to 1 million cells. The cells are small, round and filled with melanin granules that give the cells a dark black appearance. Upon introduction into
5 culture, cells migrate out from the fragments of RPE sheets that are attached to the flasks. Melanin granules are visible in greater than 95% of the migrating cells and constitute an index of RPE cell purity in the preparation. Morphologically, the RPE cells change from small, round black
10 cells to larger, cuboidal cells, with greatly diminished pigmentation as they spread outward from the RPE tissue fragments. The original morphological appearance is reacquired, upon establishment of culture confluence. At confluence, the 25 cm² culture flask yields approximately
15 5 million cells. The cells are recovered from the flask by exposure to 0.2% trypsin (radiation sterilized, qualified) for 10 minutes, followed by scraping the cells from the flask surface with a sterile spatula (CoStar, Cat. No. 3008). Scraping is necessary because the cells are very tightly
20 adherent and the extended times necessary for dissociating the cells from the flasks with trypsin digestion alone produces very low cell viability (10% or less). The combination of trypsinization and scraping produce preparations with greater than 90% viability as judged by
25 Trypan Blue dye exclusion.

RPE cells recovered from the flasks are divided into three aliquots and further processed as follows. Aliquot 1 (about 4.5 million cells) and Aliquot 2 (about 0.45 million cells) in 1 ml of antibiotic/antimycotic free-Culture Medium
30 is adjusted to a final concentration of 7.5% with DMSO (Sigma, Cat. No. D2650, qualified for endotoxin and tested in culture) and 20% qualified fetal calf serum. The cells are transferred into cryopreservation vials and frozen in a controlled rate cryopreservation apparatus (Nalge, Cryo-1-C,
35 Cat. No. 5100-001). The vials used are from Corning (Corning, Cat. No. 25704). Aliquot III is utilized for immunoperoxidase staining, immunofluorescent staining and

immunohistochemistry staining for known markers for RPE cells. The cells are plated onto sterile, multi well glass slices coated with Pronectin F, the cells allowed to attach overnight in the culture incubator and then further evaluated
5 for the presence of markers to judge the purity of the RPE cells in culture include the presence of cytokeratin, vesicular dopamine transporter protein, and tyrosine hydroxylase.

10 6.1.2. ELISA ASSAYS OF CONDITIONED MEDIUM

RPE cells were isolated and cultured as described above in section 6.1.1, except that the collagenase utilized was from SigmaType 1a (Cat. No. C-9891 and also two culture media were utilized in different experiments as described.
15 Initially, the cells were placed in either DMEM-F12 culture medium (Gibco, Cat. No. 12440-20 and 1765-021) or in RPMI 1640 (Gibco, Cat. No. 21870-084). Both culture media were supplemented with 2mM glutamine, 10% fetal calf serum, an antibiotic/antimycotic reagent and acidic FGF (10 ng/ml).
20 The cells were plated in culture flasks coated either with mouse laminin (Gibco, Cat. No. L2020) or with Pronectin F (Protein Technologies, Cat. No. 5002-00, Lot. No. RO117-C). The RPE cells were grown to confluence and passaged in either the DMEM/F12 medium containing 10% fetal calf serum or in
25 RPMI 1640 containing 2% fetal calf serum. When using DMEM/F12, the cells were plated onto flasks coated with laminin. If using the RPMI 1640 medium, the cells were subcultured onto ProNectin coated flasks.

When the RPE cells had reached confluence, the culture
30 media was harvested and stored frozen at -80° C until assayed for the presence of Fas L by ELISA or bioassay with fetal thymocytes. The ELISA assay protocol includes the following steps. Ninety-six well plates (quality Biologicals, Cat. No. 3791) are coated with anti-human Fas L antibody (Santa Cruz
35 Biotech, Cat. No. SC-956 or Pharmingen, Cat. No. 65431a) by adding 100 ul/well of a stock antibody solution (10 ug antibody/ml) and allowing coating to proceed overnight in the

cold room. The 96-well plates are then washed three times with 0.5 ml of phosphate buffered saline (PBS, Irvine Scientific, Cat. No. 9240) containing 0.05% Tween (Tween-20, BioRad, Cat. No. 170-6531). Non-specific protein binding was then minimized by coating unbound sites on the plates with 200 ul of 1% bovine serum albumin (Amersham, Cat. No. RPN 412) in PBS. After standing for 2 hrs at 37° C, the blocking solution is decanted and the wells washed once with 0.5 ml of PBS-Tween. The plates prepared as above were further incubated either with Fas L peptide (Santa Cruz Biotech, Cat. No. SC 956 L, 0-100 ng in 100 ul PBS to generate a standard curve) or with 100 ul of conditioned medium harvested from RPE cell (passage 0, through passage 9). After the Fas L peptide or Fas L in the conditioned medium had bound to the plates for 1 hour at room temperature, the plates were washed three times with PBS-Tween. A second, biotinylated, anti-human Fas L antibody was added to form a sandwich (Biotinylated NoK-1 antibody, Pharmingen, Cat. No. 65322, 100 ul of a 5 ug/ml solution). After binding for 1 hr at room temperature, the unbound antibody was washed off the plates with 3 washes of PBS-Tween. Avidin-horse radish peroxidase solution (ABC Vectrastain, Vector Labs, Cat. No. PK-6100) was then added at 50 ul per well and the binding to biotin-antibody performed by incubation for 30 min at room temperature. The unbound avidin-horse radish peroxidase was removed with three washes of PBS-Tween. One-hundred ul of OPD solution was then added for color development. The OPD (orthophenylenediamine, Sigma, Cat. No. P6662) solution was prepared by dissolving OPD at 0.5 mg/ml in 50mM phosphate-citrate buffer, pH 5.0 (Sigma, Cat. No. P-4922) containing 1% hydrogen peroxide. After suitable color development had occurred by incubation of the plates at room temperature, the reaction was stopped by the addition of 2 N sulfuric acid solution (Sigma, Cat. No. S. 1526). The absorption of the plates was determined on a Bio-Tek Microplate BioKinetics plate reader (Model EL 340) using a 490 nm filter.

Standard curves were generated using the N-terminal 22 amino acid synthetic peptide of Fas L (SC0567). The peptide was added to culture medium with supplements identical to those used for cell culture) to generate a standard curve, 5 with 0-60 ng Fas L peptide per 200 ul of reaction medium.

6.1.3. FAS L INDUCED APOPTOSIS BIOASSAYS

To determine whether the cross reacting material was capable of inducing apoptosis, as is the case with intact 10 Fas L (surface bound or free), bioassays were performed.

Apoptosis of lymphocyte populations is inducible upon the interaction of cell surface bound Fas with its ligand, Fas L. Induction of apoptosis requires, however, that the lymphocytes be activated (i.e., as by treatment with anti CD3 15 antibodies for T cell subsets). Fetal thymocytes are in a high state of activation *in vivo* and can be used for apoptosis studies *in vitro*, without the requirement for activation.

The experimental protocol with fetal thymocytes was as 20 follows. 7.5 million freshly isolated human fetal thymocytes (ABR, Inc.) were incubated in 5 ml of fresh medium or RPE cell conditioned-medium (DMEM/F12 medium containing 10% fetal calf serum) for 6-12 hours. RPE cell conditioned medium used in the assays had been previously screened for Fas L content 25 by ELISA assays and contained Fas L cross reacting material in a concentration range of 0-13 ng/100 ul of conditioned medium.

Following the incubation, the cells were spun down in a centrifuge (5 min at 100 rpm) and the cell pellet fix, 30 permeabilized and stained and using the APO-DIRECT™ kit provided by Pharmingen. Staining involved the use of propidium iodide for total DNA content and the use of FITC-dUTP and terminal deoxynucleotide transferase to label DNA chain breaks. Two color FACS analyses were performed to 35 quantitate I propidium iodide and FITC-dUMP fluorescence, using a Beckton-Dickinson FACS scan cell sorter. Electronic

gating was utilized to eliminate cell aggregates. The data presented therefore relates to single cells.

6.2. RESULTS

5 6.2.1. RESULTS OF THE ELISA ASSAYS

Standard Curves were generated using the N-terminal 22 amino acid synthetic peptide of Fas L (Sc9567). The standard curve data generated are indicated below.

10	SC9567 Conc. ng/200 ul	Absorbancy (490 nM)	Average	Standard Dev.
	0	0.044, 0.046	0.045	0.001
	2.5	0.072, 0.076	0.074	0.002
	5.0	0.161, 0.121	0.143	0.029
15	10.0	0.151, 0.197	0.174	0.033
	60.0	0.517, 0.629	0.573	0.079

Using the values for the standard curve above, the values of Fas L cross reacting material in RPE cell-conditioned medium (RPE CM) (values per 100 ul aliquot) were
20 calculated, using the Santa Cruz anti-Fas L antibody and are listed below.

25

30

35

	Sample Analyzed	Mean Absorbancy (490 nm)	Standard Deviation (Absorption)	ng Fas L (Per 100 ul)
5	Control medium	0.063	0.001	2.5
	RPE CM (DMEM/F12, P0)	0.091	0.004	5.2
	RPE CM (DMEM/F12, P1)	0.114	0.017	6.5
10	RPE CM (DMEM/F12, P3)	0.115	0.02	6.6
	RPE CM (RPMI 1640, P0)	0.139	0.033	8.0
	RPE CM (RPMI 1640, P1)	0.292	0.044	17.0
15	RPE CM (RPMI 1640, P2)	0.228	0.031	13.0
	RPE CM (RPMI 1640, P0)	0.157	0.011	9.0
	RPE CM (RPMI 1640, P1)	0.130	0.013	7.5
20	RPE CM (RPMI 1640, P1)	0.202	0.004	12.0
	RPE CM (DMEM/F12, P0)	0.167	0.006	9.6

ELISA assays of late passage RPE cells grown in RPMI 1640 + 2% or + 10% fetal calf serum or DMEM/F12 + 10% fetal calf serum are shown below. In the former case, the cells were plated on Pronectin F coated flasks, whereas in the latter case, the cells were plated on mouse laminin. Calculations of the mass of Fas L are normalized at the absorbancy at 490 nm for the SC9567 Fas L peptide value at 5 ng/assay. A control for medium not exposed to RPE cells is also included. The results are as follows:

Cells grown in DMEM/F12 + 10 % FCS

5	Sample	Mean Absorbance (490 nm)	Standard Deviation (Absorbancy)	Fas L (Ng/100 ul)
	SC9567, 5 ng	0.461	0.001	5.0
	Control Medium	0.063	0.007	0.7
	RPE CM, P4	0.870	0.124	9.4
10	RPE CM, P5	0.544	0.101	6.0
	RPE CM, P6	0.442	0.120	4.7
	RPE CM, P7	0.136	0.025	1.5
	RPE CM, P8	0.529	0.160	5.7
	RPE CM, P9	0.793	0.191	8.6

15

Cells Grown in RPMI 1640 + 2% FCS

20	Sample	Mean Absorbance (490 nm)	Standard Deviation (Absorbancy)	Fas L (Ng/100 µl)
	SC9567, 5 ng	0.461	0.001	5.0
	RPMI Control Medium	0.085	0.012	0.9
	RPE CM, P4	0.628	0.087	7.0
25	RPE CM, P5	0.395	0.039	4.3
	RPE CM, P6	0.427	0.066	4.6
	RPE CM, P7	0.379	0.086	4.1
	RPE CM, P8	0.524	0.026	5.7

30

35

Cells grown in RPMI 1640 + 10% FCS

	Sample	Mean Absorbance (490 nm)	Standard Deviation (Absorbancy)	Fas L (Ng/100 μ l)
5	SC9567, 5 ng	0.461	0.001	5.0
	RPMI Control Medium	0.049	0.000	0.5
	RPE CM, P4	0.653	0.070	7.0
	RPE CM, P5	0.418	0.120	4.5
10	RPE CM, P6	0.452	0.039	5.8
	RPE CM, P7	0.425	0.018	4.6
	RPE CM, P8	0.359	0.073	4.0

15 6.2.2. EVALUATION OF THE RPE CONDITIONED MEDIUM FOR
APOPTOSIS-INDUCING ACTIVITY AGAINST THYMOCTYES

The results described above indicate that the RPE cells release material into the culture medium that is immunologically related to the N-terminal peptide of Fas ligand in assays with the antibody preparation from Santa Cruz BioTech. Similar experiments were performed using anti-Fas L antibody obtained from Pharmingen, which confirmed the presence of Fas L cross-reacting material.

20 Negative control or positive control cells are treated with FITC-dUTP in the presence of TdT enzyme. This leads to the incorporation of FITC-dUTP into the DNA fragments found in apoptotic cells. Cells are then stained with propidium iodide and analyzed on a Beckton Dickinson FACSCAN™. The presence of apoptotic cells is demonstrated by increased fluorescence intensity as apoptotic cells are clearly labeled with FITC (yellow-green cells), while non-apoptotic cells show only the red staining of propidium iodide.

30 The results of the FACS analysis are presented in Fig. 1 and are summarized in the accompanying table inserts of Fig. 2. To briefly summarize, apoptosis in the thymocytes incubated in fresh medium (not exposed to RPE cells) was approximately 12%. No indication of apoptosis was seen until

the Fas L concentration of the RPE CM had reached its highest value, i.e., 13 ng/100 ul of conditioned medium. At this point, the apoptotic value had risen to 24% or to approximately twice that of the control medium. The failure
5 to see apoptosis generated at lower Fas L concentrations may indicate that the Fas L is significantly degraded or may indicate that the apoptosis inducing activity is marginal as the free ligand until high concentrations are attained.

10

15

20

25

30

35

WE CLAIM:

1. A method of creating an immune privileged site wherein said method comprises administering RPE cells in an amount effective to create an immunologically privileged site.
2. A method of treating a disease in a mammal wherein said method comprises administering RPE cells that supply a therapeutic protein or biologically active molecule to a mammal in need of said treatment, wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and sustain a therapeutic effect.
3. A method of treating a disease in a mammal wherein said method comprises co-administering of RPE cells with cells that supply a therapeutic protein or other biologically active molecule, wherein said RPE cells are administered in an amount effective to create an immunologically privileged site and cells that supply a therapeutic protein or other biologically active molecule are administered in an amount effective to sustain a therapeutic effect.
4. The method of Claim 2 or 3 wherein said therapeutic protein or other biologically active molecule consist of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, peptide growth or differentiation factor, interleukin, chemokine, interferon, neurotransmitter, colony stimulating factor or angiogenic factor.
5. The method of Claim 3 wherein said cells that produce said therapeutic molecule are cells transformed by a nucleic acid encoding said therapeutic protein or other biologically active molecule.

3
6. The method of Claim 1, 2 or 3 wherein the RPE cells, or the co-administered cells, are attached to a matrix prior to administration.

5 7. The method of Claim 1, 2 or 3 wherein said administering is by transplantation.

8. The method of Claim 2 wherein the RPE cells are transformed by a nucleic acid encoding said therapeutic
10 protein or other biologically active molecule.

9. The method of Claim 1, 2 or 3 wherein said RPE cells are administered in a dose ranging from 10^3 to 10^7 cells.
15

10. The method of Claim 3 wherein said cells that produce said biological factor are administered in a dosage of from 10^3 to 10^7 cells.

20 11. The method of Claim 7 wherein said transplantation is by xenograft.

12. The method of Claim 7 wherein said transplantation is by allograft.

25 13. The method of Claim 2 or 3 wherein the disease consists of a neurological, cardiac, endocrine, hepatic, pulmonary, metabolic or immunological disease.

30 14. The method of Claim 1, 2 or 3 wherein the RPE cells are re-administered in an effective amount to sustain an immunologically privilege site.

15. The method of Claim 2 or 3 wherein the RPE cells,
35 or co-administered cells that supply the therapeutic protein or other biologically active molecule are re-administered in an effective amount to sustain a therapeutic effect.

16. A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein or other biologically active molecule and a pharmaceutically acceptable carrier.

5

17. A pharmaceutical composition comprising RPE cells attached to a matrix.

18. A pharmaceutical composition comprising RPE cells and cells that produce a therapeutic protein, or other biologically active molecule, are attached to a matrix.

19. The composition of Claim 16 wherein therapeutic protein, or other biologically active molecule consists of a growth factor, cytokine, hormone, peptide fragment of a hormone, inhibitor of cytokines, peptide growth or differentiation factor, interleukin, chemokine, interferon, colony stimulating factor or angiogenic factor.

20. A pharmaceutical composition comprising RPE cells and a pharmaceutically acceptable carrier.

21. A compartmentalized kit adapted to receive a first container adapted to contain RPE cells and a second container adapted to contain cells that produce a therapeutic molecule that is absent or defective in a disease.

22. A compartmentalized kit adapted to receive a first container adapted to contain RPE cells and a second container adapted to contain pancreatic islet of Langerhans cells.

23. An article of manufacture comprising a packaging material and RPE cells contained within said packaging material, wherein said RPE cells are effective for creating an immunologically privileged site in a mammal, and wherein said packaging material contains a label that indicates that

said cells can be used for creating an immunologically privileged site in a mammal.

24. A method for producing Fas L comprising (i)
5 culturing RPE cells which express the Fas L; and (ii)
recovering the Fas L from the cell culture.

10

15

20

25

30

35

ABSTRACT OF THE INVENTION

The present invention relates to a novel *in vivo* method for creation of a localized immunosuppressive environment in
5 tissue. The method involves the transplanting of pigmented
retinal epithelial cells into a mammal thereby producing a
localized immunosuppressive environment. The transplanted
pigmented retinal epithelial cells may also be used to
produce therapeutic proteins or other biologically active
10 molecules that may be useful in treatment of diseases.

15

20

25

30

35

66240-ETH0000










FIG. 1

Rgn	Events	% Gated
1 R1	4972	100.00
2 R2	1212	24.38

FIG. 2

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

USE OF PIGMENTED RETINAL EPITHELIAL CELLS FOR CREATING OF AN IMMUNE PRIVILEGED SITE

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on _____ (if applicable)
☐ was filed in the United States on _____ as Application Serial No. _____ (for declaration not accompanying application)
 with amendment(s) filed on _____ (if applicable)
☐ was filed as PCT international application Serial No. _____ on _____ and was amended under PCT Article 19
 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaanni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Albert P. Halluin (Reg. No. 25227), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Ann L. Gisolfi (Reg. No. 31956), SaraLynn Mandel (Reg. No. 31853), Mark A. Farley (Reg. No. 33170), James G. Markey (Reg. No. 31636), and Charles F. Hoyng (Reg. No. 35548), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 2730 Sand Hill Road, Menlo Park, CA 94025, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO: PENNIE & EDMONDS 1155 AVENUE OF THE AMERICAS NEW YORK, N.Y. 10036-2711						DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME ALLEN	FIRST NAME RICHARD	MIDDLE NAME C.			
	RESIDENCE & CITIZENSHIP	CITY FLEMINGTON	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP USA			
	POST OFFICE ADDRESS	STREET 155 HILLCREST ROAD	CITY FLEMINGTON	STATE OR COUNTRY NEW JERSEY	ZIP CODE 08822		
202	FULL NAME OF INVENTOR	LAST NAME CORNFELDT	FIRST NAME MICHAEL	MIDDLE NAME L.			
	RESIDENCE & CITIZENSHIP	CITY MORRISTOWN	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP USA			
	POST OFFICE ADDRESS	STREET 22 CANTERBURY WAY	CITY MORRISTOWN	STATE OR COUNTRY NEW JERSEY	ZIP CODE 07960		
203	FULL NAME OF INVENTOR	LAST NAME KIDWELL	FIRST NAME WILLIAM	MIDDLE NAME R.			
	RESIDENCE & CITIZENSHIP	CITY IJAMSVILLE	STATE OR FOREIGN COUNTRY MARYLAND	COUNTRY OF CITIZENSHIP USA			
	POST OFFICE ADDRESS	STREET 10905 LOWELL COURT	CITY IJAMSVILLE	STATE OR COUNTRY MARYLAND	ZIP CODE 21754		
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME			
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP			
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE		
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME			
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP			
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE		
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME			
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP			
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
DATE	DATE	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE